Clinical Trial Update: Study to Assess the Effect of Rifampicin on Blood Levels and Safety of AZD9291, in Patients With EGFRm+ NSCLC [Phase 1]

View source ↗

Summary

Phase 1 study assessing the effect of rifampicin on blood levels and safety of AZD9291 in patients with EGFRm+ non-small cell lung cancer has completed with res…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• AZD9291 (osimertinib)

Snippet

Sponsor: AstraZeneca | Conditions: Non Small Cell Lung Cancer | Phase 1 | Status: COMPLETED | Results posted: 2016-09-28